Toll-like Receptor 2 Down-regulation in Established Mouse Allergic Lungs Contributes to Decreased Mycoplasma Clearance
- 1 April 2008
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 177 (7), 720-729
- https://doi.org/10.1164/rccm.200709-1387oc
Abstract
Rationale: Respiratory Mycoplasma pneumoniae (Mp) infection is involved in asthma pathobiology, but whether the established allergic airway inflammation compromises lung innate immunity and subsequently predisposes patients with asthma to Mp infection remains unknown. Objectives: To test whether the established allergic airway inflammation compromises host innate immunity (e.g., Toll-like receptor 2 [TLR2]) to hinder the elimination of Mp from the lungs. Methods: We used mouse models of ovalbumin (OVA)-induced allergic airway inflammation with an ensuing Mp infection, and cultures of mouse primary lung dendritic cells (DCs) and bone marrow–derived DCs. Measurements and Main Results: Lung Mp clearance in allergic mice and TLR2 and IL-6 levels in lung cells, including DCs as well as cultured primary lung DCs and bone marrow–derived DCs, were assessed. The established OVA-induced allergic airway inflammation, or the prominent Th2 cytokines IL-4 and IL-13, inhibited TLR2 expression and IL-6 production in lung cells, including lung DCs, and eventually led to impaired host defense against Mp. Studies in IL-6 knockout mice indicated that IL-6 directly promoted Mp clearance from the lungs. IL-4– and IL-13–induced suppression of TLR2 was mediated by inhibiting nuclear factor-κB activation through signal transducer and activator of transcription 6 (STAT6) signaling pathway. Conclusions: The established OVA-induced allergic airway inflammation impairs TLR2 expression and host defense cytokine (e.g., IL-6) production, and subsequently delays lung bacterial clearance. This could offer novel therapeutic strategies to reinstate TLR2 activation by using TLR2 ligands and/or blocking IL-4 and IL-13 to ameliorate persisting respiratory bacterial infections in allergic lungs.Keywords
This publication has 50 references indexed in Scilit:
- Intranasal Interleukin-12 Therapy InhibitsMycoplasma pneumoniaeClearance and Sustains Airway Obstruction in Murine PneumoniaInfection and Immunity, 2008
- Mycoplasma pneumoniae and its role in asthmaPublished by Oxford University Press (OUP) ,2007
- IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infectionMicrobes and Infection, 2007
- Respiratory Tract Infection with Mycoplasma pneumoniae in Interleukin-12 Knockout Mice Results in Improved Bacterial Clearance and Reduced Pulmonary InflammationInfection and Immunity, 2007
- Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathwaysClinical and Experimental Immunology, 2006
- Roles of Interleukin‐6 in Activation of STAT Proteins and Recruitment of Neutrophils duringEscherichia coliPneumoniaThe Journal of Infectious Diseases, 2006
- The role of epithelial Toll-like receptor expression in host defense and microbial toleranceInnate Immunity, 2005
- Antifungal Immune Reactivity in Nasal PolyposisInfection and Immunity, 2004
- IL-4–independent pathways exacerbate methacholine-induced airway hyperreactivity during mycoplasma respiratory diseaseJournal of Allergy and Clinical Immunology, 2004
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.The Journal of Experimental Medicine, 1992